Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462889 | 1.00 | TAAR1 (0.62) | TAAR1KMT2ATSHRACHEDAO | |
| SCHEMBL282555 | 1.00 | TAAR1 (0.62) | TAAR1KMT2ATSHRACHEDAO | |
| Water SCHEMBL27889910 | 0.97 | TAAR1 (0.60) | TAAR1KMT2ATSHRACHEDAO | |
| SCHEMBL2236079 | 0.91 | TAAR1 (0.54) | TAAR1KMT2ATSHRACHEDAO | |
| SCHEMBL9360089 | 0.91 | TAAR1 (0.54) | TAAR1KMT2ATSHRDAOCA12 | |
| SCHEMBL8598519 | 0.87 | TAAR1 (0.50) | TAAR1KMT2ADAOCA12CA1 | |
| Phenol SCHEMBL28184726 | 0.87 | TAAR1 (0.50) | TAAR1KMT2ADAOCA12CA1 | |
| SCHEMBL6546756 | 0.86 | TAAR1 (0.48) | TAAR1KMT2ATSHRACHECTBP2 | |
| SCHEMBL143962 | 0.86 | TAAR1 (0.71) | TAAR1KMT2ATSHRACHEDAO | |
| SCHEMBL29981544 | 0.85 | TAAR1 (0.58) | TAAR1KMT2ATSHRACHEDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | TAAR1 3913/4885KMT2A 2085/4885TSHR 4176/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | TAAR1 3855/4885KMT2A 2092/4885TSHR 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.